Barclays analyst Saket Kalia lowered the firm’s price target on Definitive Healthcare (DH) to $3 from $4 and keeps an Underweight rating on the shares. The company reported billings and revenue a bit better than expectations, but customer down-selling continues and churn got worse in Q4, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DH:
- Dell reports mixed Q4 results, Intel delays Ohio chip factory: Morning Buzz
- Definitive Healthcare Corp: Hold Rating Amid Retention Challenges and Strategic Opportunities
- Positive Long-Term Outlook for Definitive Healthcare Corp Despite Current Challenges
- Cautious Outlook on Definitive Healthcare Corp Amid Mixed Signals and Challenges
- Definitive Healthcare Corp. Reports 2024 Financial Results